Jeffrey Embt
Vermögen: 175 734 $ am 31.08.2026
Vermögen: 175 734 $ am 31.08.2026
Mr. Jeffrey D.
Embt, CPA, is a Chief Accounting Officer at JELD-WEN Holding, Inc. Mr. Embt was previously employed as a Chief Accounting Officer by Proterra, Inc., a Chief Financial Officer by Proterra Operating Co., Inc., and a Head-Finance by BWXT Medical Ltd. He received his undergraduate degree from Coastal Carolina University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.02.2026 | 73’529 ( 0.08% ) | 175 734 $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| JELD-WEN HOLDING, INC. | Comptroller/Controller/Auditor | 05.01.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
Proterra Operating Co., Inc.
Proterra Operating Co., Inc. Auto Parts: OEMProducer Manufacturing Manufactures zero-emission electric powertrain transit solutions for medium and heavy duty commercial vehicles | Finanzdirektor/CFO | 01.12.2025 |
| PROTERRA INC. | Comptroller/Controller/Auditor | 01.02.2024 |
BWXT Medical Ltd.
BWXT Medical Ltd. Part of BWX Technologies, Inc., BWXT Medical Ltd. is a Canadian company specializing in the development, manufacturing, and supply of advanced radiopharmaceutical products and medical isotopes for diagnostic imaging and targeted radiotherapeutic treatments. The company is based in Toronto, Canada. BWXT Medical offers a portfolio that includes isotopes such as actinium-225, germanium-68, indium-111, iodine-123, strontium-82, and technetium-99m generators, supporting clinical trials and patient treatments in more than 40 countries. The company produces radiochemicals, APIs, radiopharmaceutical unit doses, and automation solutions in a cGMP/GLP facility, and provides contract manufacturing for products like TheraSphere™ for liver cancer treatment. BWXT Medical collaborates with partners such as TRIUMF, Bayer AG, and Fusion Pharmaceuticals to advance nuclear medicine technologies and participates in organizations supporting the medical isotope sector. The CEO of the company is Jonathan W. Cirtain. | Finanzdirektor/CFO | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Proterra Operating Co., Inc.
Proterra Operating Co., Inc. Auto Parts: OEMProducer Manufacturing Manufactures zero-emission electric powertrain transit solutions for medium and heavy duty commercial vehicles | Producer Manufacturing |
Coastal Carolina University
Coastal Carolina University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
JELD-WEN Holding, Inc.
JELD-WEN Holding, Inc. Forest ProductsNon-Energy Minerals Manufactures doors, windows and related products | Non-Energy Minerals |
BWXT Medical Ltd.
BWXT Medical Ltd. Part of BWX Technologies, Inc., BWXT Medical Ltd. is a Canadian company specializing in the development, manufacturing, and supply of advanced radiopharmaceutical products and medical isotopes for diagnostic imaging and targeted radiotherapeutic treatments. The company is based in Toronto, Canada. BWXT Medical offers a portfolio that includes isotopes such as actinium-225, germanium-68, indium-111, iodine-123, strontium-82, and technetium-99m generators, supporting clinical trials and patient treatments in more than 40 countries. The company produces radiochemicals, APIs, radiopharmaceutical unit doses, and automation solutions in a cGMP/GLP facility, and provides contract manufacturing for products like TheraSphere™ for liver cancer treatment. BWXT Medical collaborates with partners such as TRIUMF, Bayer AG, and Fusion Pharmaceuticals to advance nuclear medicine technologies and participates in organizations supporting the medical isotope sector. The CEO of the company is Jonathan W. Cirtain. | |
Proterra, Inc.
Proterra, Inc. Motor VehiclesConsumer Durables Designs and manufactures zero-emission electric transit vehicles | Consumer Durables |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen